Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2021-01-14 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - ANP 5 pages 27.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Antisense Therapeutics Limited. It details the number of securities to be issued, the type of securities, the proposed issue date, and other related information about the placement. There is no financial report, earnings data, or management discussion. The content fits the description of a Capital/Financing Update, which covers company fundraising and capital structure changes. The document is not a full report but an announcement of a financing activity.
2021-01-14 English
Appendix 2A 14 pages 299.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being issued, and references to ASX Listing Rules and regulatory requirements. This form is used to notify the exchange and the market about new securities being quoted, typically following a capital raising or issuance event. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement related to capital structure changes. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is the actual announcement, not just a brief notice or a report publication announcement.
2021-01-14 English
Change of Registered Office and Principal Place of Business 1
Regulatory Filings Classification · 95% confidence The document is a short announcement from Antisense Therapeutics Limited regarding a change of its registered office and principal place of business address. It references ASX Listing Rule 3.14, which relates to company information updates. The document does not contain financial data, management changes, voting results, or any other detailed report content. It is a regulatory announcement about company details, fitting best under Regulatory Filings (RNS). The document length is only 814 characters, indicating it is a brief notice rather than a full report or presentation.
2021-01-13 English
Ceasing to be a substantial holder 3 pages 126.1KB
Director's Dealing Classification · 100% confidence The document contains multiple entries of share disposals by Platinum Investment Management Limited, detailing dates, nature of change, consideration amounts, and number of shares affected. This is a clear report of personal share transactions by a company director or related party. There is no indication of financial results, meeting materials, or regulatory announcements beyond these transactions. The document length is short and focused solely on share dealings. Therefore, the document fits the definition of Director's Dealing (DIRS).
2021-01-10 English
2020 Annual General Meeting Presentation 15 pages 2.6MB
AGM Information Classification · 95% confidence The document is titled 'AGM Presentation December 2020' and contains detailed information typically presented at an Annual General Meeting (AGM), including corporate overview, financial highlights, research analyst reports, progress updates, clinical trial data, capital raising information, and Q&A sections related to corporate and clinical development plans. The presence of forward-looking statements, shareholder information, and detailed corporate and clinical updates aligns with materials shared during an AGM. There is no indication that this is a full annual report (10-K), earnings release, or other regulatory filing. The document is a presentation format, consistent with AGM Information filings.
2020-12-17 English
Annual General Meeting Chairman's Address 2 pages 167.9KB
AGM Information Classification · 95% confidence The document is titled 'Chairman’s Address to Antisense Therapeutics 2020 Annual General Meeting' and is dated December 18, 2020. It contains a detailed speech from the Chairman addressing shareholders about the company's progress, clinical trial results, regulatory designations, pipeline developments, and shareholder support. The content is typical of a Chairman's speech delivered at an Annual General Meeting (AGM), focusing on company performance and outlook rather than presenting full financial statements or detailed financial analysis. The document length is about 5700 characters, which is consistent with a speech or presentation rather than a full Annual Report or Interim Report. There is a direct reference to the Annual Report for more comprehensive details, indicating this document is supplementary to the formal report. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM.
2020-12-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.